For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

and Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to ...

Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...

The National Rosacea Society has opened its applications for research funding as the grant program celebrates its 25th anniversary, according to a press release.

Pre-market: 6:21:55 am GMT-5 ...